top of page

ANAVEX New Website - Untitled Page.png

Search

Sigma-1 Receptor Agonists Inhibit Oligodendrocyte Cytotoxicity Induced by Molecules

Feb 11, 2016

ACTRIMS Forum 2016, New Orleans, Louisiana

Robert P. Lisak M.D., Liljana Nedelkoska, Joyce A. Benjamins, Ph.D., Department of Neurology, Wayne State University School of Medicine, Detroit, Michigan

View Poster

Recent Posts

Anavex Life Sciences Announces Issuance of Blarcamesine (ANAVEX®2-73) Composition of Matter U.S. Patent Expanding its Intellectual Property Portfolio

Anavex Life Sciences Announces Peer-Reviewed Publication of Oral Blarcamesine Phase IIb/III Data in The Journal of Prevention of Alzheimer’s Disease

New Phase IIb/III Clinical Data Demonstrates Over Three Years of Continuous Treatment with Oral Blarcamesine to Significantly Benefit Early Alzheimer’s Disease Patients

bottom of page